메뉴 건너뛰기




Volumn 26, Issue 4, 2008, Pages 238-246

Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects

Author keywords

Aliskiren; Direct renin inhibitor; Diuretic; Furosemide; Isosorbide mononitrate

Indexed keywords

ALISKIREN; FUROSEMIDE; ISMO RETARD; ISOSORBIDE 5 NITRATE; RENIN INHIBITOR; UNCLASSIFIED DRUG;

EID: 55849133073     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2008.00058.x     Document Type: Article
Times cited : (13)

References (30)
  • 1
    • 43449108927 scopus 로고    scopus 로고
    • Aliskiren. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
    • Aliskiren. US Prescribing Information. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 2007.
    • (2007) US Prescribing Information
  • 3
    • 33947182655 scopus 로고    scopus 로고
    • Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension
    • Oh B-H, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007 49 : 1157 1163.
    • (2007) J Am Coll Cardiol , vol.49 , pp. 1157-1163
    • Oh, B.-H.1    Mitchell, J.2    Herron, J.R.3    Chung, J.4    Khan, M.5    Keefe, D.L.6
  • 4
    • 14844363404 scopus 로고    scopus 로고
    • Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients
    • Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005 111 : 1012 1018.
    • (2005) Circulation , vol.111 , pp. 1012-1018
    • Gradman, A.H.1    Schmieder, R.E.2    Lins, R.L.3    Nussberger, J.4    Chiang, Y.5    Bedigian, M.P.6
  • 5
    • 33845366982 scopus 로고    scopus 로고
    • Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide
    • Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, Zhang J. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007 25 : 217 226.
    • (2007) J Hypertens , vol.25 , pp. 217-226
    • Villamil, A.1    Chrysant, S.G.2    Calhoun, D.3    Schober, B.4    Hsu, H.5    Matrisciano-Dimichino, L.6    Zhang, J.7
  • 7
    • 36248931230 scopus 로고    scopus 로고
    • Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy
    • Drummond W, Munger MA, Essop MR, Maboudian M, Khan M, Keefe DL. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens 2007 9 : 742 750.
    • (2007) J Clin Hypertens , vol.9 , pp. 742-750
    • Drummond, W.1    Munger, M.A.2    Essop, M.R.3    Maboudian, M.4    Khan, M.5    Keefe, D.L.6
  • 8
    • 34447521458 scopus 로고    scopus 로고
    • Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial
    • Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial. Lancet 2007 370 : 221 229.
    • (2007) Lancet , vol.370 , pp. 221-229
    • Oparil, S.1    Yarows, S.A.2    Patel, S.3    Fang, H.4    Zhang, J.5    Satlin, A.6
  • 9
    • 33947223136 scopus 로고    scopus 로고
    • Aliskiren, a novel renin inhibitor, is well tolerated and has sustained BP-lowering effects alone or in combination with HCTZ during long-term (52 weeks) treatment of hypertension
    • Sica D, Gradman AH, Lederballe O, Meyers M, Cai J, Keefe DL. Aliskiren, a novel renin inhibitor, is well tolerated and has sustained BP-lowering effects alone or in combination with HCTZ during long-term (52 weeks) treatment of hypertension. Eur Heart J 2006 27 (Suppl. 121.
    • (2006) Eur Heart J , vol.27 , pp. 121
    • Sica, D.1    Gradman, A.H.2    Lederballe, O.3    Meyers, M.4    Cai, J.5    Keefe, D.L.6
  • 10
    • 39849089447 scopus 로고    scopus 로고
    • Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: A 6-month, randomized, double-blind trial
    • Andersen K, Weinberger MH, Egan B, Constance CM, Ali MA, Jin J, Keefe DL. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: A 6-month, randomized, double-blind trial. J Hypertens 2008 26 : 589 599.
    • (2008) J Hypertens , vol.26 , pp. 589-599
    • Andersen, K.1    Weinberger, M.H.2    Egan, B.3    Constance, C.M.4    Ali, M.A.5    Jin, J.6    Keefe, D.L.7
  • 11
    • 34447621764 scopus 로고    scopus 로고
    • Antihypertensive efficacy, safety and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: A pooled analysis
    • Weir MR, Bush C, Anderson DR, Zhang J, Keefe DL, Satlin A. Antihypertensive efficacy, safety and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: A pooled analysis. J Am Soc Hypertens 2007 1 : 264 277.
    • (2007) J Am Soc Hypertens , vol.1 , pp. 264-277
    • Weir, M.R.1    Bush, C.2    Anderson, D.R.3    Zhang, J.4    Keefe, D.L.5    Satlin, A.6
  • 12
    • 33749853955 scopus 로고    scopus 로고
    • Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers
    • Vaidyanathan S, Valencia J, Kemp C, Zhao C, Yeh C-M, Bizot M-N, Denouel J, Dieterich H-A, Dole WP. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int J Clin Pract 2006 60 : 1343 1356.
    • (2006) Int J Clin Pract , vol.60 , pp. 1343-1356
    • Vaidyanathan, S.1    Valencia, J.2    Kemp, C.3    Zhao, C.4    Yeh, C.-M.5    Bizot, M.-N.6    Denouel, J.7    Dieterich, H.-A.8    Dole, W.P.9
  • 13
    • 53349090037 scopus 로고    scopus 로고
    • Effect of aliskiren, an oral direct renin inhibitor, on the pharmacokinetics and pharmacodynamics of a single dose of acenocoumarol in healthy volunteers
    • Huang H-LA, Vaidyanathan S, Yeh C-M, Bizot M-N, Dieterich H-A, Dole WP, Howard D. Effect of aliskiren, an oral direct renin inhibitor, on the pharmacokinetics and pharmacodynamics of a single dose of acenocoumarol in healthy volunteers. Curr Med Res Opin 2008 24 : 2449 2456.
    • (2008) Curr Med Res Opin , vol.24 , pp. 2449-2456
    • H-La, H.1    Vaidyanathan, S.2    Yeh, C.-M.3    Bizot, M.-N.4    Dieterich, H.-A.5    Dole, W.P.6    Howard, D.7
  • 14
    • 28044453329 scopus 로고    scopus 로고
    • Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine
    • Dieterle W, Corynen S, Vaidyanathan S, Mann J. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther 2005 43 : 527 535.
    • (2005) Int J Clin Pharmacol Ther , vol.43 , pp. 527-535
    • Dieterle, W.1    Corynen, S.2    Vaidyanathan, S.3    Mann, J.4
  • 16
    • 28044468751 scopus 로고    scopus 로고
    • Aliskiren, a novel oral renin inhibitor, has no interaction with cytochrome P450 isoenzymes in vitro
    • Vaidyanathan S, Jin Y, Schiller H, Jensen C. Aliskiren, a novel oral renin inhibitor, has no interaction with cytochrome P450 isoenzymes in vitro. Basic Res Pharmacol Toxicol 2005 97 (Suppl. 1 239.
    • (2005) Basic Res Pharmacol Toxicol , vol.97 , Issue.1 , pp. 239
    • Vaidyanathan, S.1    Jin, Y.2    Schiller, H.3    Jensen, C.4
  • 17
    • 33644789557 scopus 로고    scopus 로고
    • Renin inhibition with aliskiren: Where are we now, and where are we going?
    • Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: Where are we now, and where are we going? J Hypertens 2006 24 : 243 256.
    • (2006) J Hypertens , vol.24 , pp. 243-256
    • Azizi, M.1    Webb, R.2    Nussberger, J.3    Hollenberg, N.K.4
  • 18
    • 0025720085 scopus 로고
    • A combined single and multiple dose pharmacokinetic study of oral isosorbide-5-mononitrate in healthy volunteers
    • Storm G, Oosterhuis B, Bron J, Wittebrood AJ, De Jong AP, Jonkman JH. A combined single and multiple dose pharmacokinetic study of oral isosorbide-5-mononitrate in healthy volunteers. Biopharm Drug Dispos 1991 12 : 661 672.
    • (1991) Biopharm Drug Dispos , vol.12 , pp. 661-672
    • Storm, G.1    Oosterhuis, B.2    Bron, J.3    Wittebrood, A.J.4    De Jong, A.P.5    Jonkman, J.H.6
  • 19
    • 33749850285 scopus 로고    scopus 로고
    • Aliskiren, the first in a new class of orally effective renin inhibitors, has no clinically significant drug interactions with digoxin in healthy volunteers
    • Dieterich H-A, Kemp C, Vaidyanathan S, Yeh C-M. Aliskiren, the first in a new class of orally effective renin inhibitors, has no clinically significant drug interactions with digoxin in healthy volunteers. Clin Pharmacol Ther 2006 79 (Suppl. 64.
    • (2006) Clin Pharmacol Ther , vol.79 , pp. 64
    • Dieterich, H.-A.1    Kemp, C.2    Vaidyanathan, S.3    Yeh, C.-M.4
  • 21
    • 0025238474 scopus 로고
    • Furosemide (frusemide). a pharmacokinetic/pharmacodynamic review (Part I)
    • Ponto LL, Schoenwald RD. Furosemide (frusemide). A pharmacokinetic/ pharmacodynamic review (Part I). Clin Pharmacokinet 1990 18 : 381 408.
    • (1990) Clin Pharmacokinet , vol.18 , pp. 381-408
    • Ponto, L.L.1    Schoenwald, R.D.2
  • 22
    • 0020535325 scopus 로고
    • Biotransformation of furosemide in kidney transplant patients
    • Smith DE, Benet LZ. Biotransformation of furosemide in kidney transplant patients. Eur J Clin Pharmacol 1983 24 : 787 790.
    • (1983) Eur J Clin Pharmacol , vol.24 , pp. 787-790
    • Smith, D.E.1    Benet, L.Z.2
  • 23
    • 0028874981 scopus 로고
    • Extrahepatic metabolism of frusemide in anaesthetized rabbits
    • Verges J, Heroux L, Maurice H, du Souich P. Extrahepatic metabolism of frusemide in anaesthetized rabbits. Br J Pharmacol 1995 116 : 2407 2412.
    • (1995) Br J Pharmacol , vol.116 , pp. 2407-2412
    • Verges, J.1    Heroux, L.2    Maurice, H.3    Du Souich, P.4
  • 24
    • 0034072174 scopus 로고    scopus 로고
    • Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions
    • Bakos E, Evers R, Sinko E, Varadi A, Borst P, Sarkadi B. Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol 2000 57 : 760 768.
    • (2000) Mol Pharmacol , vol.57 , pp. 760-768
    • Bakos, E.1    Evers, R.2    Sinko, E.3    Varadi, A.4    Borst, P.5    Sarkadi, B.6
  • 25
    • 47049093197 scopus 로고    scopus 로고
    • Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans
    • Fisher ND, Jan Danser AH, Nussberger J, Dole WP, Hollenberg NK. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008 117 : 3199 3205.
    • (2008) Circulation , vol.117 , pp. 3199-3205
    • Fisher, N.D.1    Jan Danser, A.H.2    Nussberger, J.3    Dole, W.P.4    Hollenberg, N.K.5
  • 26
    • 44949088665 scopus 로고    scopus 로고
    • Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics
    • Vallon V, Rieg T, Ahn SY, Wu W, Eraly SA, Nigam SK. Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics. Am J Physiol Renal Physiol 2008 294 : F867 873.
    • (2008) Am J Physiol Renal Physiol , vol.294
    • Vallon, V.1    Rieg, T.2    Ahn, S.Y.3    Wu, W.4    Eraly, S.A.5    Nigam, S.K.6
  • 27
    • 0023215206 scopus 로고
    • Isosorbide 5-mononitrate pharmacokinetics
    • Chasseaud LF. Isosorbide 5-mononitrate pharmacokinetics. Cardiology 1987 74 (Suppl. 1 6 11.
    • (1987) Cardiology , vol.74 , Issue.1 , pp. 6-11
    • Chasseaud, L.F.1
  • 28
    • 34547628374 scopus 로고    scopus 로고
    • Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment
    • Vaidyanathan S, Bigler H, Yeh C, Bizot MN, Dieterich HA, Howard D, Dole WP. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet 2007 46 : 661 675.
    • (2007) Clin Pharmacokinet , vol.46 , pp. 661-675
    • Vaidyanathan, S.1    Bigler, H.2    Yeh, C.3    Bizot, M.N.4    Dieterich, H.A.5    Howard, D.6    Dole, W.P.7
  • 29
    • 41149087776 scopus 로고    scopus 로고
    • A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects
    • Ayalasomayajula S, Tchaloyan S, Yeh C-M, Bizot M-N, Dieterich H-A, Howard D, Dole WP. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects. CMRO 2008 24 : 717 726.
    • (2008) CMRO , vol.24 , pp. 717-726
    • Ayalasomayajula, S.1    Tchaloyan, S.2    Yeh, C.-M.3    Bizot, M.-N.4    Dieterich, H.-A.5    Howard, D.6    Dole, W.P.7
  • 30
    • 0029074273 scopus 로고
    • Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation
    • Kosoglou T, Patrick JE, Cohen A, Radwanski E, Christopher D, Affrime MB. Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation. Clin Ther 1995 17 : 241 251.
    • (1995) Clin Ther , vol.17 , pp. 241-251
    • Kosoglou, T.1    Patrick, J.E.2    Cohen, A.3    Radwanski, E.4    Christopher, D.5    Affrime, M.B.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.